CA3154392A1 - Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases - Google Patents
Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases Download PDFInfo
- Publication number
- CA3154392A1 CA3154392A1 CA3154392A CA3154392A CA3154392A1 CA 3154392 A1 CA3154392 A1 CA 3154392A1 CA 3154392 A CA3154392 A CA 3154392A CA 3154392 A CA3154392 A CA 3154392A CA 3154392 A1 CA3154392 A1 CA 3154392A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- asp
- animals
- phagocytes
- 64zne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3293959A CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/055770 WO2021071499A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3293959A Division CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3154392A1 true CA3154392A1 (en) | 2021-04-15 |
Family
ID=68387423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154392A Pending CA3154392A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| CA3293959A Pending CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3293959A Pending CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11779597B2 (https=) |
| EP (1) | EP4041214A1 (https=) |
| JP (4) | JP7634895B2 (https=) |
| AU (1) | AU2019470001B2 (https=) |
| CA (2) | CA3154392A1 (https=) |
| WO (1) | WO2021071499A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0472053B1 (en) * | 1990-08-20 | 1998-06-17 | Eisai Co., Ltd. | Sulfonamide derivatives |
| JP2790926B2 (ja) * | 1990-08-20 | 1998-08-27 | エーザイ株式会社 | スルホンアミド誘導体 |
| US6162350A (en) | 1997-07-15 | 2000-12-19 | Exxon Research And Engineering Company | Hydroprocessing using bulk Group VIII/Group VIB catalysts (HEN-9901) |
| WO2015185602A1 (en) | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
| US10226484B2 (en) * | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| US20160153957A1 (en) | 2014-12-01 | 2016-06-02 | Peter Y. Novak | Method for diagnostics of pathology in biologocal objects |
| JP7003045B2 (ja) * | 2016-02-11 | 2022-02-04 | シェヴィオン モデハイ | 神経変性の治療のための方法及び医薬組成物 |
| CN106581056A (zh) * | 2016-10-11 | 2017-04-26 | 徐志强 | 锌在制造治疗帕金森病药物的用途 |
| US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
| US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
-
2019
- 2019-10-11 JP JP2022522035A patent/JP7634895B2/ja active Active
- 2019-10-11 US US17/768,190 patent/US11779597B2/en active Active
- 2019-10-11 CA CA3154392A patent/CA3154392A1/en active Pending
- 2019-10-11 WO PCT/US2019/055770 patent/WO2021071499A1/en not_active Ceased
- 2019-10-11 AU AU2019470001A patent/AU2019470001B2/en active Active
- 2019-10-11 EP EP19795409.2A patent/EP4041214A1/en active Pending
- 2019-10-11 CA CA3293959A patent/CA3293959A1/en active Pending
-
2023
- 2023-08-28 US US18/238,817 patent/US12036238B2/en active Active
-
2024
- 2024-01-05 JP JP2024000684A patent/JP2024038270A/ja not_active Withdrawn
-
2025
- 2025-07-04 JP JP2025113738A patent/JP2025148408A/ja active Pending
- 2025-11-25 JP JP2025202951A patent/JP2026035686A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019470001B2 (en) | 2024-09-19 |
| NZ787735A (en) | 2025-03-28 |
| WO2021071499A1 (en) | 2021-04-15 |
| US11779597B2 (en) | 2023-10-10 |
| JP7634895B2 (ja) | 2025-02-25 |
| JP2022551943A (ja) | 2022-12-14 |
| JP2024038270A (ja) | 2024-03-19 |
| US20240173350A1 (en) | 2024-05-30 |
| CA3293959A1 (en) | 2026-03-02 |
| AU2019470001A1 (en) | 2022-05-12 |
| US12036238B2 (en) | 2024-07-16 |
| JP2025148408A (ja) | 2025-10-07 |
| JP2026035686A (ja) | 2026-03-04 |
| US20230210894A1 (en) | 2023-07-06 |
| EP4041214A1 (en) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrabi et al. | Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti‐apoptotic effects of melatonin | |
| Gao et al. | Tetrahydroxy stilbene glycoside alleviated inflammatory damage by mitophagy via AMPK related PINK1/Parkin signaling pathway | |
| ES2685947T3 (es) | Agentes antienvejecimiento | |
| JP5736421B2 (ja) | 生理学的過程の調節およびこれに有用な薬剤 | |
| TWI452039B (zh) | 抗神經變性疾病用劑 | |
| US6174875B1 (en) | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke | |
| JP2018021033A (ja) | ペプチド治療薬およびその使用方法 | |
| Mao et al. | Glutamate cascade to cAMP response element-binding protein phosphorylation in cultured striatal neurons through calcium-coupled group I metabotropic glutamate receptors | |
| JP2021507945A (ja) | 認知症を含む神経障害のための組成物および治療方法 | |
| CN115645388A (zh) | 氨基酸组合物及其用途 | |
| JP2026035686A (ja) | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 | |
| Jiang et al. | The correlation between accumulation of amyloid beta with enhanced neuroinflammation and cognitive impairment after intraventricular hemorrhage | |
| Saadi et al. | Spatial, temporal, and cell-type-specific expression of NADPH Oxidase isoforms following seizure models in rats | |
| US12383554B2 (en) | Compositions and methods to protect mammalian tissue against cold and other metabolic stresses | |
| Sun et al. | Histone deacetylase inhibitors reduce cysts by activating autophagy in polycystic kidney disease | |
| Li et al. | Bilberry anthocyanins attenuate mitochondrial dysfunction via β-catenin/TCF pathway in Alzheimer’s disease | |
| CA3093212A1 (en) | Compounds for treating alzheimer's disease | |
| CN116919932A (zh) | 成骨剂及其用途 | |
| EP1977748B1 (en) | Compounds having neuroprotective properties | |
| RU2839611C1 (ru) | Средство для лечения болезни паркинсона | |
| Wang et al. | Activation of SIRT3 alleviates neurodegeneration via rescuing mitochondrial succinate dehydrogenase activity and bioenergy supply in rotenone-induced PD models | |
| US20240217946A1 (en) | Antidepressant and anxiolytic substituted cinnamamide compound | |
| KR102478582B1 (ko) | 에버닉산을 유효성분으로 함유하는 파킨슨 질환 예방 또는 치료용 조성물 | |
| POZDNYAKOV et al. | RESEARCH RESULTS IN PHARMACOLOGY | |
| WO2025046207A1 (en) | New use of a pde 5 inhibitor combination in promoting neurite outgrowth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221111 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240815 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241008 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241008 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241011 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241212 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250327 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250408 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250408 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250730 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250730 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250930 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250930 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20251127 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260307 |